Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Tuesday, Eledon Pharmaceuticals Inc (NASDAQ:ELDN) announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with tegoprubart for the prevention of pancreatic islet cell transplant rejection in type 1 diabetes patients.
週二，Eledon Pharmicals Inc（納斯達克股票代碼：ELDN）宣佈，研究者主導的臨床試驗的第一位參與者已接受胰島細胞移植，並正在接受tegoprubart治療，以預防1型糖尿病患者的胰腺胰島細胞移植排斥反應。
The company also reported updated data from its ongoing Phase 1b trial as of April 2024 from 13 participants, demonstrating that tegoprubart is generally safe and well-tolerated and supports tegoprubart's potential to protect organ function in patients undergoing kidney transplantation.
該公司還報告了截至2024年4月正在進行的1b期試驗的最新數據，這些數據來自13名參與者，這表明tegoprubart總體上是安全的，耐受性良好，並支持tegoprubart在保護接受腎臟移植的患者器官功能方面的潛力。
Aggregate mean estimated glomerular filtration rate (eGFR) – a measure of kidney function – measured above 60 mL/min/1.73m2 at all reported time points after day 30.
在第30天之後的所有報告時間點，累計平均腎小球濾過率（eGFR）（衡量腎臟功能的指標）均高於60 mL/min/1.73m2。
Two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year.
兩名受試者在移植後接受了12個月的治療，並且每年的平均表皮生長因子均超過90 mL/min/1.73m2。
To date, three subjects discontinued the study because of hair loss and fatigue, viral infection, and rejection, respectively.
迄今爲止，有三名受試者分別因脫髮和疲勞、病毒感染和排斥反應而停止了這項研究。
There have been no cases of graft loss or death.
沒有移植物流失或死亡的案例。
Eledon is currently conducting a Phase 1b trial, the Phase 2 BESTOW trial, and a Long-Term Safety and Efficacy extension study to evaluate tegoprubart for the prevention of organ rejection in kidney transplant patients.
Eledon目前正在進行一項1b期試驗、BESTOW二期試驗和一項長期安全性和有效性擴展研究，以評估tegoprubart在預防腎移植患者器官排斥反應方面的作用。
Concurrently, Eledon Pharmaceuticals announced a private placement of approximately $50 million, offering 13.1 million shares at $2.37 per share and pre-funded warrants at $2.369 per underlying share, which are exercisable to purchase 7.99 million shares.
同時，Eledon Pharmicals宣佈進行約5000萬美元的私募配售，以每股2.37美元的價格發行1,310萬股股票，以每股標的2.369美元的價格發行預先籌集資金的認股權證，可行使購買799萬股股票。
HC Wainwright suggests that islet cell transplantation could be a promising way to reverse type 1 diabetes by restoring metabolic control without relying on insulin injections. The analyst highlights tegopruibart's potential to decrease or replace intensive anti-rejection drugs without causing side effects.
HC Wainwright認爲，通過在不依賴胰島素注射的情況下恢復代謝控制，胰島細胞移植可能是逆轉1型糖尿病的一種有前途的方法。該分析師強調了tegopruibart在不引起副作用的情況下減少或替代強效抗排斥藥物的潛力。
HC Wainwright reiterates the Buy rating, and with increased confidence in tegoprubart's probability of advancement into a pivotal study, it has raised the price target from $13 to $16.
HC Wainwright重申了買入評級，隨着人們對tegoprubart進入關鍵研究的可能性的信心增強，該公司已將目標股價從13美元上調至16美元。
The analyst continues to look for the potential signing of a licensing collaboration agreement, including an upfront payment worth up to $100 million, for further development and commercialization of tegoprubart around the 2025 timeframe as a future catalyst.
該分析師繼續尋找簽署許可合作協議的可能性，包括價值高達1億美元的預付款，用於在2025年前後進一步開發和商業化tegoprubart，以此作爲未來的催化劑。
Price Action: ELDN shares are down 9.63% at $2.21 at last check Tuesday.
價格走勢：週二最後一次檢查時，ELDN股價下跌9.63％，至2.21美元。
譯文內容由第三人軟體翻譯。